IL6 and congenital rubella syndrome: Patients who do not respond to the first dose of tocilizumab might be less likely to respond to subsequent repeat administration of this agent; for these patients, consideration should be given to administration of corticosteroids — weighing the risks and benefits of steroid use for CRS and the uncertain risk of suppressing CAR T cell expansion — and/or alternative agents, such as the anti-IL-6 monoclonal antibody siltuximab37,38,111.